Calquence: Data from P3 ESCALADE trial (NCT04529772) for DLBCL post 2026 (AstraZeneca) - Feb 5, 2025 - Q4 & FY2024 Results: Data from P2 TrAVeRse trial (NCT05951959) in combination with venetoclax and rituximab for treatment-naïve MCL post 2026
P2 data • P3 data • Chronic Lymphocytic Leukemia • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Oncology
|